Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 4Phase 1/2 2Phase 1 2Phase 2/3 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 127Colonic Neoplasms 71Rectal Neoplasms 56Neoplasm Metastasis 22Pancreatic Neoplasms 20Stomach Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Leukemia 11Carcinoma, Hepatocellular 11Neoplasms 10Lymphoma 10Burkitt Lymphoma 8Adenocarcinoma Of Esophagus 8Cholangiocarcinoma 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Esophageal Neoplasms 5Leukemia, Biphenotypic, Acute 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Digestive System Neoplasms 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Gallbladder Neoplasms 3Biliary Tract Neoplasms 3Rectal Diseases 2Neurotoxicity Syndromes 2

Interventions

Cisplatin 21Radiotherapy 16Fluorouracil 16Paclitaxel 14Irinotecan 7Docetaxel 7Neoadjuvant Therapy 6Drug Therapy 5tislelizumab 4sintilimab 4Surgical Procedures, Operative 4Radiation 4Oxaliplatin 4Leucovorin 4Esophagectomy 4Capecitabine 4toripalimab 3pembrolizumab 3TP protocol 3Chemotherapy, Adjuvant 3S 1 (combination) 2Levoleucovorin 2Cetuximab 2Carboplatin 2lenvatinib 1irinotecan sucrosofate 1durvalumab 1atropine sulfate-diphenoxylate hydrochloride drug combination 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Squamous Cell Carcinoma × Leucovorin × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04460352 2025-03-06

NEEDS

Karolinska University Hospital

Phase 3 Recruiting
1,020 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Sun Yat-sen University

Phase 3 Not yet recruiting
360 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡